BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 31229554)

  • 1. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
    Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
    Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
    Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
    Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
    Pariyar R; Bastola T; Lee DH; Seo J
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
    Haque ME; Azam S; Akther M; Cho DY; Kim IS; Choi DK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: A comparative study.
    Yadav SK; Pandey S; Singh B
    J Chem Neuroanat; 2017 Nov; 85():50-59. PubMed ID: 28711564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
    Bao XQ; Wu LY; Wang XL; Sun H; Zhang D
    Naunyn Schmiedebergs Arch Pharmacol; 2015 May; 388(5):549-56. PubMed ID: 25678053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poloxamer 188-mediated anti-inflammatory effect rescues cognitive deficits in paraquat and maneb-induced mouse model of Parkinson's disease.
    Ding W; Lin H; Hong X; Ji D; Wu F
    Toxicology; 2020 Apr; 436():152437. PubMed ID: 32169474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP
    Luo D; Zhao J; Cheng Y; Lee SM; Rong J
    Mol Neurobiol; 2018 Mar; 55(3):2258-2267. PubMed ID: 28321769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
    Ho SC; Hsu CC; Pawlak CR; Tikhonova MA; Lai TJ; Amstislavskaya TG; Ho YJ
    Behav Brain Res; 2014 Jul; 268():177-84. PubMed ID: 24755306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning.
    Kinoshita K; Tada Y; Muroi Y; Unno T; Ishii T
    Life Sci; 2015 Sep; 137():28-36. PubMed ID: 26209139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta.
    Cankara FN; Günaydın C; Bilge SS; Özmen Ö; Kortholt A
    Neurosci Lett; 2020 Nov; 738():135308. PubMed ID: 32932183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720 Inhibits MPP
    Yao S; Li L; Sun X; Hua J; Zhang K; Hao L; Liu L; Shi D; Zhou H
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):478-492. PubMed ID: 31069623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.